A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease

  • End date
    Jun 23, 2024
  • participants needed
  • sponsor
    Viela Bio (acquired by Horizon Therapeutics)
Updated on 23 April 2022


This study aims to define the efficacy and safety of inebilizumab for the prevention of flare of IgG4-related disease (IgG4-RD).


After a screening period of up to 28 days, subjects with IgG4-RD at high risk of flare due to multi-organ disease and recent active disease will be randomized in a 1:1 ratio to receive intravenous (IV) inebilizumab or placebo after premedication during the 52-week randomized control period (RCP). All subjects will receive an initial tapering dose of glucocorticoids (GCs) to complete treatment of their active disease. Flares occurring during study will be treated. The primary endpoint is time to a first adjudication committee-determined, investigator-treated disease flare during the RCP.. The primary analysis will be conducted when the last subject completes the RCP visit or discontinues the RCP. This study includes an optional 52-week open-label treatment period. The expected duration of each subject's participation in this study is up to 400 days (screening and RCP) or, for eligible subjects who enroll in the optional OLP, up to 813 days (screening, RCP, interval between RCP and OLP, and OLP).

Condition IgG4 Related Disease
Treatment Placebo, Inebilizumab
Clinical Study IdentifierNCT04540497
SponsorViela Bio (acquired by Horizon Therapeutics)
Last Modified on23 April 2022


Yes No Not Sure

Inclusion Criteria

Male or female adults, ≥ 18 years of age at time of informed consent
Clinical diagnosis of IgG4-RD
Fulfillment of the 2019 ACR/EULAR classification criteria
Experiencing (or recently experienced) an IgG4-RD flare that requires initiation or continuation of glucocorticoid (GC) treatment at the time of informed consent
IgG4-RD affecting at least 2 organs/sites at any time in the course of IgG4-RD
Non-sterilized male subjects who are sexually active with a female partner of childbearing potential must use a condom with spermicide from Day 1 through to the end of the study and must agree to continue using such precautions for at least 6 months after the final dose of IP. Females of childbearing potential who are sexually active with a non-sterilized male partner must use a highly effective method of contraception

Exclusion Criteria

History of solid organ or cell-based transplantation or known immunodeficiency disorder
Active malignancy or history of malignancy that was active within the last 10 years (some specific situations for cervical, skin or prostate cancer are acceptable)
Receipt of any biologic B cell-depleting therapy or non-depleting B-cell-directed therapy in prior 6 months
Receipt of non-biologic DMARD or immunosuppressive agent other than GCs within prior 4 weeks
Active tuberculosis or high risk for tuberculosis; hepatitis C infection in absence of curative treatment; evidence of hepatitis B infection
Live vaccine or therapeutic agent in prior 2 weeks
Glomerular filtration rate < 30 mL/min/1.73 m2
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note